<?xml version='1.0' encoding='utf-8'?>
<document id="32286940"><sentence text="Clinical Pharmacokinetics of Propranolol Hydrochloride: A Review."><entity charOffset="29-54" id="DDI-PubMed.32286940.s1.e0" text="Propranolol Hydrochloride" /></sentence><sentence text="Nobel laureate Sir James Black's molecule, propranolol, still has broad acceptance in cardiovascular diseases, infantile haemangiomas and anxiety"><entity charOffset="43-54" id="DDI-PubMed.32286940.s2.e0" text="propranolol" /></sentence><sentence text=" A comprehensive and systematic review of the literature for the summarization of pharmacokinetic parameters would be effective in order to explore the new safe uses of propranolol in different scenarios, without exposing humans and using virtual-human modeling approaches"><entity charOffset="169-180" id="DDI-PubMed.32286940.s3.e0" text="propranolol" /></sentence><sentence text="" /><sentence text="This review encompasses physico-chemical properties, pharmacokinetics and drug-drug interaction data of propranolol collected from various studies"><entity charOffset="104-115" id="DDI-PubMed.32286940.s5.e0" text="propranolol" /></sentence><sentence text="" /><sentence text="Clinical pharmacokinetic studies on propranolol were screened using Medline and Google scholar's databases"><entity charOffset="36-47" id="DDI-PubMed.32286940.s7.e0" text="propranolol" /></sentence><sentence text=" Eighty-three clinical trials, in which pharmacokinetic profiles and plasma time concentration were available after oral or IV administration, were included in the review" /><sentence text="" /><sentence text="The study depicts that propranolol is well absorbed after oral administration"><entity charOffset="23-34" id="DDI-PubMed.32286940.s10.e0" text="propranolol" /></sentence><sentence text=" It has dose-dependent bioavailability, and a 2-fold increase in dose results in 2" /><sentence text="5-fold increase in the area under the curve, 1" /><sentence text="3-fold increase in the time to reach maximum plasma concentration and finally, 2" /><sentence text="2 and 1" /><sentence text="8-fold increase in maximum plasma concentration in both immediate and long-acting formulations, respectively" /><sentence text=" Propranolol is a substrate of CYP2D6, CYP1A2 and CYP2C19, retaining potential pharmacokinetic interactions with co-administered drugs"><entity charOffset="1-12" id="DDI-PubMed.32286940.s16.e0" text="Propranolol" /></sentence><sentence text=" Age, gender, race and ethnicity do not alter its pharmacokinetics" /><sentence text=" However, in renal and hepatic impairment, it needs a dose adjustment" /><sentence text="" /><sentence text="Physiochemical and pooled pharmacokinetic parameters of propranolol are beneficial in order to establish physiologically based pharmacokinetic modeling among the diseased population"><entity charOffset="56-67" id="DDI-PubMed.32286940.s20.e0" text="propranolol" /></sentence><sentence text="" /></document>